Drug Pricing
Our work in Drug Pricing
-
Is Investing in Research to Delay Aging of Value Today?
The time is ripe for a new frontier in medicine.
Categorized in -
Would Price Transparency for Generic Drugs Lower Costs for Payers and Patients?
In 2016, roughly 62,000 retail pharmacies filled over 4.4 billion drug prescriptions, costing almost $400 billion and accounting for more than 10 percent of overall U.S. health care spending. Almost 9 of 10 retail prescriptions—4 billion—were for low-cost generic drugs, accounting for about $100 billion in drug spending. The actual cost of generic drugs is […]
Categorized in -
Look for Savings in Drug Distribution Chain, Researchers Urge
In the face of growing popular concern over prescription drug prices, opportunities may exist for significant savings in the drug distribution chain, according to two papers presented.
Categorized in -
Fostering Competition in the Pharmaceutical Distribution Chain
Although a great deal of attention concerning prescription drug prices centers on the prices charged by pharmaceutical manufacturers themselves, markups in the distribution chain—pharmacy benefit managers, wholesalers, and pharmacies—are often substantial. Despite the large role that these actors play, little is known about the discounts they negotiate or markups they charge and how those relate […]
Categorized in -
Follow the Money: The Flow of Funds in the Pharmaceutical Distribution System
Any government intervention to control drug pricing should be predicated on a clear understanding of the economic forces that drive price increases, and the parties responsible for them.
Categorized in -
New Report Documents the Flow of Money Through the Pharmaceutical Distribution Chain
The study found that for every $100 spent on retail prescription drugs in the US, the manufacturer received $58, of which about $17 goes direct production costs. The remaining $41 accrues to intermediaries in the pharmaceutical distribution chain.
Categorized in -
Value-Based Drug Pricing Makes Sense, But is Difficult to Pull Off
There are challenges of value-based pricing and health technology assessments.
Categorized in -
Flow of Money Through the Pharmaceutical Distribution System
For every $100 spent at retail pharmacies, about $17 compensates for direct production costs, $41 accrues to the manufacturer, and $41 accrues to intermediaries in the distribution system.
Categorized in -
Real‐World Resource Use and Costs of Haemophilia A‐Related Bleeding
This study assesses hemophilia A‐related resource use and cost by treatment type (prophylaxis versus non‐prophylaxis) and any associated cost savings.
Categorized in -
Measuring Indirect Costs (Productivity and Caregiver Burden) in the ACC/AHA Guideline Statin Benefit Groups
This study estimated the annual costs of productivity loss and caregiver burden for four statin benefit groups.
Categorized in